Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DBV Technologies

- PMLiVE

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation

- PMLiVE

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

Aimmune’s Palforzia is first peanut allergy drug cleared in US

Shares in the Nasdaq-listed biotech have spiked

- PMLiVE

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

- PMLiVE

Nestlé Health Science invests $145m in food allergy biotech

Aimmune Therapeutics' lead product is a phase III peanut allergy treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links